Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

CALC

Phase 2

Auxora™

asparaginase-induced pancreatic toxicity (AIPT)

2025

CRSPA/AIPT study. Ph1/2 trial initial patient cohort results presented at ASH '23. Enrolling in Ph2 portion.Data in 2025.

Data readout

KYMR

Phase 1

KT-294

Autoimmune and inflammatory diseases

H2 2025

Initiate Phase 1 clinical trial in H1 2025 and report results in H2 2025.

Data readout

ANRO

Phase 2

ALTO-101

Cognitive Impairment Associated with Schizophrenia

H2 2025

6/20/24- Initiated Ph2 trial with top-line data in H2 2025.

Data readout

IMAB

Phase 2

Uliledlimab (TJD5) (TJ004309) (anti-CD73)+ toripalimab

NSCLC (Non-small cell lung cancer)

H2 2025

w/TJ Biopharma, ongoing Ph2 combination study. Data in 2H 2025.

Data readout

IOVA

Phase 2

Iovance TIL (LN-145)

NSCLC (Non-small cell lung cancer)

2025

IOV-LUN-202. Meet w/ FDA in early 2024 to discuss a registrational trial. 12/27/23- Placed on clinical hold on 12/22/23. Presented Cohort 3A data at IASLC/WCLC '23. 3/4/24- Clinical hold lifted. Complete enrollment & report data in 2025.

Data readout

OCUL

Phase 3

AXPAXLI (OTX-TKI) (axitinib intravitreal implant)

Wet Age-Related Macular Degeneration (wet AMD) and other retinal diseases.

Q4 2025

SOL-1 & SOL-R trials. 2/13/24- Ph3 first subjects screened in SOL-1. 7/30/24- First patients enrolled in SOL-R. 8/7/24- FDA feedback as registrational study. 1/14/25- Shared SOL-R enrollment progress. SOL-1 topline data in Q4 2025.

Data readout

DNLI

Phase 2/3

DNL343 (eIF2B Activator)

ALS (Amyotrophic lateral sclerosis)

2025

HEALEY ALS trial. 5/1/24- Complete enrollment in Regimen G. 1/6/25- Reported Ph2/3 topline data for Regimen G, endpoints not met. Additional analyses in 2025.

Additional Data readout

ZNTL

Phase 2

Azenosertib (ZN-c3) (oral inhibitor of WEE1)

USC (Uterine Serous Carcinoma)

H2 2025

TETON or ZN-c3-004 study. 8/2/21- Ph2 initiated. 11/9/22- Ph2 mono data. 6/18/24- FDA placed partial clinical hold. 9/16/24 Lifts clinical hold.Topline data in H2 '25.

Data Readout

NRIX

Phase 1a/b

NX-5948

Waldenstrom’s Macroglobulinemia

2025

10/18/24- Present positive data at IWWM 12. 12/19/24- Granted FDA Fast Track Designation. Continue to enroll in the ongoing Ph1b expansion cohort with add'l clinical data in 2025.

Data readout

PTN

Phase 3

PL9643

DED (Dry eye disease)

Q4 2025

MELODY-1 study. 2/5/24 Database lock; 2/29/24 MELODY-1 Ph3 top-line data. Initiate MELODY-2 and the open-label MELODY-3 study in H2 2024. 4/8/24- Presented results at ASCRS '24. 5/15/24 Type C meeting w/FDA in Q3 '24. 8/28/24- FDA confirms acceptability of protocols & endpoints for MELODY 2 & 3. 10/2/24 Enrollment to start Q1 2025 with topline data in Q4 2025 & NDA in H1 '26.

Data readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20